GlobalData: Head and Neck Cancer on reports-research.com

Nov. 8, 2010 - PRLog -- The report identifies the key trends shaping and driving the global head and neck cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global head and neck cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Head and Neck Cancer Market is Market is Estimated to Roughly Double in Size by 2017

GlobalData expects the global head and neck cancer therapeutics market to grow at a rate of 7.6% annually for the next seven years to reach $1,854m by 2017. It was valued at $1,035m in 2009. This significant growth is primarily attributed to the high incidence, prevalence and diagnosis rate of the disease and the high prescription rates of the currently approved products. In addition, the successful launch of certain biologics, gene therapies and vaccines such as Reolysin, OncoVEX and nimotuzumab, currently in Phase III, may significantly stimulate market growth in the near future. However, the low treatment seeking rate and the widespread use of off-label drugs will act as barriers for market growth.

Sparsely Populated Market Consisting Of only two Approved Products (Erbitux and Taxotere)

GlobalData’s analysis has found that the current competition in the head and neck cancer market is weak. The competitive landscape is sparsely populated with only two FDA (Food and Drug Administration)-approved products. The market is characterized by high off-label usage of drugs such as cisplatin, paclitaxel carboplatin and combination therpaies. The currently marketed products are not highly efficacious and so are not able to meet market demands such as improved five-year survival rates, reductions in tumor sizes and the control of tumor recurrence. However, the development of technologically advanced products such as vaccines, gene therapy and biologics in different stages of the pipeline promises to provide better options for treatment.      

Strong Pipeline is Expected to Bring Novel and Efficacious Products to the Market      

GlobalData has found that there are 405 products in different stages of development. Reolysin, Oncovex and nimotuzumab, currently in Phase III, are some of the most promising products in the pipeline. Biologics, gene therapy, vaccines and other molecular targeted therapies make the pipeline robust enough to meet the unmet needs of the head and neck cancer market. The pipeline holds novel products which are technologically advanced and have high efficacy and safety profiles. The efficacy and safety of biologics such as nimotuzumab (approved in 23 countries and undergoing Phase III studies in the US) are high in terms of complete response, progression-free survival, improved tolerability and high safety profiles. Additionally, some of the oncolytic vaccines currently in Phase III, such as Oncovex, offer systematic benefits by inducing a potent anti-tumor immune response, as well as the prevention of new lesions and a lowering of the relapse rate.    

These products are expected to meet the market’s unmet needs and will give physicians more choice in treating head and neck cancer. It may also lead to an intensely competitive market landscape for which the existing market leaders will have to be prepared. In summary, the global head and neck cancer market is heading towards a highly competitive landscape.

Current Treatment Options Leave Significant Unmet Need

The current head and neck cancer therapeutics market is slightly competitive with only two approved products, the last of which was approved in 2004. Other marketed products, such as cisplatin, paclitaxel and carboplatin, are used as off-label drugs. This clearly indicates that the market is currently faced with a high level of unmet needs in terms of safety and efficacy. The efficacy of the currently marketed products (Taxotere and Erbitux) is moderate in terms of the management of the disease. Erbitux has a better safety profile than Taxotere, which is associated with serious adverse events. However, both of the marketed products have some serious side effects such as neutropenia, anemia, severe hypersensitivity, serious infusion reactions, cardiopulmonary arrests and severe fluid retention.  

Because the current therapeutic landscape lacks drugs with first-rate safety and efficacy profiles, the market continues to present opportunities for stronger pipeline candidates. The extent of unmet needs in the head and neck cancer therapeutics market is considered to be high and can be fulfilled by technologically-advanced products with improved safety and efficacy profiles.


GlobalData: Head and Neck Cancer – Pipeline Assessment and Market Forecast to 2017:
http://www.reports-research.com/market-surveys/head-neck-...

GlobalData: More market data and market reports:
http://www.reports-research.com/market-surveys/globaldata...

# # #

markt-studie.de founded in 2002 has emerged as a leading online portal for market surveys and market research in German speaking areas. Four years later the English language portal reports-research.com was introduced due to the extraordinary success of the portal. Again one year later estudio-mercado.es - the Spanish spoken portal - was founded. The objective of the three portals is to competently and efficiently support consultants and decision makers in management, sales and marketing in the search for worldwide market research. Prospective buyers can look into more than 60,000 market surveys from more than 200 international publishers, current market data for more than 6,000 branches worldwide, 10,000 company profiles as well as a free-of-charge research and recommendation service for individual market research.